Vanguard Capital Management
BBNX

Vanguard Capital Management’s Beta Bionics BBNX Stock Holding History

Vanguard Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Buy
1,782,346
+54,369
+3% +$647K ﹤0.01% 2269
2026
Q1 		$17.3M Buy
+1,727,977
New +$25.6M ﹤0.01% 2428

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Vanguard Capital Management's BBNX Position: Q2 2026 in Review

Vanguard Capital Management increased its Beta Bionics (BBNX) stake by 3.1% in Q2 2026, buying an estimated $647K and bringing the position to 1,782,346 shares worth $27.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Vanguard Capital Management first reported a position in BBNX in Q1 2026 and has held it in 2 quarters since. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Vanguard Capital Management held 1,782,346 shares of Beta Bionics worth $27.9M as of Q2 2026.
  • Vanguard Capital Management bought 54,369 Beta Bionics shares in Q2 2026, an estimated $647K.
  • Beta Bionics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2269 holding.
  • Vanguard Capital Management first reported a position in Beta Bionics in Q1 2026 and has held it in 2 quarters since.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.